Brentuximab vedotin
About
Therapy type: Targeted therapy
Therapy strategy: target CD30 antigens
Mappings
NCI Thesaurus: Brentuximab Vedotin (ncit:C66944)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | CD30 + | Anaplastic Large Cell Lymphoma | Brentuximab vedotin, Cyclophosphamide, Doxorubicin, Prednisone | |
| FDA (1) | CD30 + | Anaplastic Large Cell Lymphoma | Brentuximab vedotin | |
| EMA (1) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin, Dacarbazine, Doxorubicin, Vinblastine | |
| EMA (2) HSE (3) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin | |
| EMA (1) HSE (1) | CD30 + | Cutaneous T-cell Lymphoma | Brentuximab vedotin | |
| HSE (1) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin, Cisplatin, Cytarabine, Etoposide | |
| HSE (1) | CD30 +, HER2-negative | Hodgkin Lymphoma | Brentuximab vedotin, Carboplatin, Etoposide, Ifosfamide | |
| HSE (1) | CD30 + | Hodgkin Lymphoma | Bendamustine, Brentuximab vedotin |